Rationale and outcome in various cancer types in clinical practices in Japan were presented at ENA

At ENA 2020 (32nd EORTC-NCI-AACR Symposium*), Dr. Yasuhiro Ogawa, visionary inventor of the KORTUC therapy and invited by the Chair of the session, Professor Udai Banerji, Deputy Director of the Drug Development Unit at the Institution of Cancer Research, presented the rationale, clinical outcomes and the science underlying KORTUC through the online session.

* EORTC-NCI-AACR Symposium, the drug development and translational research meeting, focusing on preclinical and clinical studies, enabling and facilitating in-depth scientific discussions on the latest developments in targets and drugs for molecular targets and cancer therapeutics